|[April 15, 2014]
Research and Markets: Hexyon (Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/cw3gct/hexyon)
has announced the addition of the "Hexyon
(Prophylactic Hepatitis B Virus Vaccines) - Forecast and Market Analysis
to 2022" report to their offering.
Hexyon [Diphtheria, tetanus, pertussis (acellular, component), hepatitis
B (rDNA), inactivated poliovirus, Hib conjugate vaccine (adsorbed)] is
Sanofi Pasteur MSD's hexavalent combination vaccinethat offers
protection against infections caused by diphtheria, tetanus, pertussis,
three subtypes of poliovirus, Hib, and all known subtypes of HBV.
Overview of Hepatitis B disease, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Hexyon including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Hexyon for top seven countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain,
UK and Canada.
Key Topics Covered:
Tables & Figures
Vaccination Recommendations and Coverage Rates
For more information visit http://www.researchandmarkets.com/research/cw3gct/hexyon
[ InfoTech Spotlight's Homepage ]